Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases.
Lista S, Vergallo A, Teipel SJ, Lemercier P, Giorgi FS, Gabelle A, Garaci F, Mercuri NB, Babiloni C, Gaire BP, Koronyo Y, Koronyo-Hamaoui M, Hampel H, Nisticò R; Neurodegeneration Precision Medicine Initiative (NPMI).
Lista S, et al. Among authors: mercuri nb.
Ageing Res Rev. 2023 Feb;84:101819. doi: 10.1016/j.arr.2022.101819. Epub 2022 Dec 13.
Ageing Res Rev. 2023.
PMID: 36526257
Review.